Actimune

Goldman Sachs started coverage of Horizon Pharma PLC (NASDAQ: HZNP) with a Buy rating and $24 target price, implying 34 percent upside, on the strength of its emerging orphan franchise. 'Attractive' Story "We view HZNP as an attractive SOTP story in transformation with management using the strong...